Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights novel agents in development for aggressive B-cell lymphoma, drawing focus on the promise of bispecific antibodies, including glofitamab, epcoritamab, and mosunetuzumab, as well as allogeneic cell therapies. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Research funding from Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, and ADC Therapeutics, and consulting with Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, ADC Therapeutics, Merck, and MonteRosa.